Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

VT103

Catalog No. T62077Cas No. 2290608-13-6
Alias VT-103, VT 103

VT103 is an orally active and selective inhibitor of TEAD1 protein palmitoylation and is an analog of VT101. VT103 has potential antitumor activity by inhibiting YAP/TAZ-TEAD-promoted gene transcriptionment, blocking TEAD auto-palmitoylation, and blocking the interaction between YAP/TAZ and TEAD.VT103 can be used in the study of HER2-positive breast cancer, prostate cancer, and triple-negative breast cancer.

VT103

VT103

Purity: 98.73%
Catalog No. T62077Alias VT-103, VT 103Cas No. 2290608-13-6
VT103 is an orally active and selective inhibitor of TEAD1 protein palmitoylation and is an analog of VT101. VT103 has potential antitumor activity by inhibiting YAP/TAZ-TEAD-promoted gene transcriptionment, blocking TEAD auto-palmitoylation, and blocking the interaction between YAP/TAZ and TEAD.VT103 can be used in the study of HER2-positive breast cancer, prostate cancer, and triple-negative breast cancer.
Pack SizePriceAvailabilityQuantity
1 mg$126In Stock
5 mg$313In Stock
10 mg$496In Stock
25 mg$892In Stock
50 mg$1,450In Stock
100 mg$1,970In Stock
1 mL x 10 mM (in DMSO)$345In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "VT103"

Select Batch
Purity:98.73%
Contact us for more batch information
Resource Download
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
VT103 is an orally active and selective inhibitor of TEAD1 protein palmitoylation and is an analog of VT101. VT103 has potential antitumor activity by inhibiting YAP/TAZ-TEAD-promoted gene transcriptionment, blocking TEAD auto-palmitoylation, and blocking the interaction between YAP/TAZ and TEAD.VT103 can be used in the study of HER2-positive breast cancer, prostate cancer, and triple-negative breast cancer.
In vitro
VT103 (3 mmol/L; 4 or 24 h; NF2-deficient NCI-H226 cells) selectively disrupts YAP–TEAD1 interaction.[1]
VT103 (3 μM; HEK293T cells) appeared to be TEAD1-selective, as it does not block palmitoylation of TEAD2, TEAD3, or TEAD4.[1]
VT103 results in the disappearance of palmitoylated TEAD1 with a concomitant increase in unpalmitoylated TEAD1. VT103 shows an IC50 of 1.02 nM in the YAP reporter assay.[1]
In vivo
VT103 (0.3~10 mg/kg; p.o.; once daily; NCI-H226-tumor-bearing mice) inhibits tumor growth, with efficacy observed at 0.3 mg/kg[1]. Pharmacokinetics of VT103 in mice.[1]
AliasVT-103, VT 103
Chemical Properties
Molecular Weight410.41
FormulaC18H17F3N4O2S
Cas No.2290608-13-6
Storage & Solubility Information
StorageShipping with blue ice.
Solubility Information
DMSO: 50 mg/mL (121.83 mM), Sonication is recommended.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM2.4366 mL12.1829 mL24.3659 mL121.8294 mL
5 mM0.4873 mL2.4366 mL4.8732 mL24.3659 mL
10 mM0.2437 mL1.2183 mL2.4366 mL12.1829 mL
20 mM0.1218 mL0.6091 mL1.2183 mL6.0915 mL
50 mM0.0487 mL0.2437 mL0.4873 mL2.4366 mL
100 mM0.0244 mL0.1218 mL0.2437 mL1.2183 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy VT103 | purchase VT103 | VT103 cost | order VT103 | VT103 chemical structure | VT103 in vivo | VT103 in vitro | VT103 formula | VT103 molecular weight